Drug Profile
Research programme: antibody therapeutics - AP Biosciences
Alternative Names: T-Cube antibodies; T-Cube bi-specific antibodies; T-Cube bsAbsLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator AP Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Solid-tumours in Taiwan (Parenteral)
- 30 Nov 2020 AP Biosciences plans clinical trial in Cancer as early as Q4 2021
- 22 Aug 2017 Research programme: antibody therapeutics - AP Biosciences is available for licensing as of 22 Aug 2017. http://www.apbioinc.com/english/about/about.php